External validation of a radiomic signature to predict p16 (HPV) status from standard CT images of anal cancer patients.
Sci Rep
; 13(1): 7198, 2023 05 03.
Article
em En
| MEDLINE
| ID: mdl-37137947
ABSTRACT
The paper deals with the evaluation of the performance of an existing and previously validated CT based radiomic signature, developed in oropharyngeal cancer to predict human papillomavirus (HPV) status, in the context of anal cancer. For the validation in anal cancer, a dataset of 59 patients coming from two different centers was collected. The primary endpoint was HPV status according to p16 immunohistochemistry. Predefined statistical tests were performed to evaluate the performance of the model. The AUC obtained here in anal cancer is 0.68 [95% CI (0.32-1.00)] with F1 score of 0.78. This signature is TRIPOD level 4 (57%) with an RQS of 61%. This study provides proof of concept that this radiomic signature has the potential to identify a clinically relevant molecular phenotype (i.e., the HPV-ness) across multiple cancers and demonstrates potential for this radiomic signature as a CT imaging biomarker of p16 status.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias do Ânus
/
Neoplasias Orofaríngeas
/
Infecções por Papillomavirus
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article